Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	Hepatology 2012 (546 pages, free PDF) Hepatitis C 2012 (150 pages, free PDF)	Free Medical Books

HIV Infection

Free Subscription Articles published in Antivir Ther Retrieve available abstracts of 128 articles: HTML format Text format

Single Articles

April 2012
1. PROTOPOPESCU C , Raffi F, Brunet-Francois C, Salmon D, et al
   Incidence, medical and socio-behavioural predictors of psychiatric events in an 11-year follow-up of HIV-infected patients on antiretroviral therapy.
   Antivir Ther. 2012 Apr 27. doi: 10.3851/IMP2102.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. WORODRIA W , Menten J, Massinga-Loembe M, Mazakpwe D, et al
   Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection.
   Antivir Ther. 2012 Apr 27. doi: 10.3851/IMP2108.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. SCHIPANI A , Egan D, Dickinson L, Davies G, et al
   Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults.
   Antivir Ther. 2012 Apr 4. doi: 10.3851/IMP2095.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   March 2012
4. BASTARD JP , Soulie C, Fellahi S, Haim-Boukobza S, et al
   Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
   Antivir Ther. 2012 Mar 21. doi: 10.3851/IMP2093.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. PLAZA Z , Soriano V, Vispo E, Del Mar Gonzalez M, et al
   Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.
   Antivir Ther. 2012 Mar 21. doi: 10.3851/IMP2091.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. THAO VP , Le T, Torok EM, Yen NT, et al
   HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam.
   Antivir Ther. 2012 Mar 21. doi: 10.3851/IMP2092.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. MEHTA SH , Kirk GD, Astemborski J, Sulkowski MS, et al
   Stability of liver fibrosis among HCV-infected injection drug users.
   Antivir Ther. 2012 Mar 15. doi: 10.3851/IMP2085.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. PAHUJA M , Grobler A, Glesby MJ, Karim F, et al
   Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South Africa.
   Antivir Ther. 2012 Mar 13. doi: 10.3851/IMP2087.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. AMMASSARI A , Trotta MP, Shalev N, Marconi P, et al
   Beyond virological suppression: the role of adherence in the late HAART era.
   Antivir Ther. 2012 Mar 13. doi: 10.3851/IMP2084.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. MOYLE GJ , Andrade-Villanueva J, Girard PM, Antinori A, et al
    A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
    Antivir Ther. 2012 Mar 2. doi: 10.3851/IMP2083.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2012
11. CURRAN A , Martinez E, Podzamczer D, Lonca M, et al
    Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO Trial.
    Antivir Ther. 2012 Feb 28. doi: 10.3851/IMP2081.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. KRENTZ HB , Cosman I, Lee K, Ming JM, et al
    Pill burden in HIV infection: 20 years of experience.
    Antivir Ther. 2012 Feb 23. doi: 10.3851/IMP2076.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. BITTAR R , Giral P, Aslangul E, Assoumou L, et al
    Determinants of low-density lipoprotein particle diameter during antiretroviral therapy including protease inhibitors in HIV-1-infected patients.
    Antivir Ther. 2012 Feb 9. doi: 10.3851/IMP2065.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. PASQUIER C , Moinard N, Saune K, Daudin M, et al
    Antiviral effect of maraviroc in semen: a case report.
    Antivir Ther. 2012 Feb 1. doi: 10.3851/IMP2038.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2012
15. MENCARELLI A , Francisci D, Renga B, D'Amore C, et al
    Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-gamma-dependent manner.
    Antivir Ther. 2012 Jan 25. doi: 10.3851/IMP2039.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. BORREGO P , Calado R, Marcelino JM, Bartolo I, et al
    Baseline susceptibility of primary HIV-2 to entry inhibitors.
    Antivir Ther. 2012 Jan 25. doi: 10.3851/IMP1996.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. CASTRO E , Recordon-Pinson P, Cavassini M, Fleury H, et al
    Multiclass primary antiretroviral drug resistance in a patient presenting HIV-1/2 dual infection.
    Antivir Ther. 2012 Jan 25. doi: 10.3851/IMP2024.
    PubMed     Text format     Related articles   
    
    
    
    
18. PETERSON K , Rowland-Jones S
    Novel agents for the treatment of HIV-2 infection.
    Antivir Ther. 2012 Jan 25. doi: 10.3851/IMP2031.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. MARCELIN AG , Descamps D, Tamalet C, Cottalorda J, et al
    Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Antivir Ther. 2012;17:119-123.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. BOUFASSA F , Goujard C, Viard JP, Carlier R, et al
    Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.
    Antivir Ther. 2012;17:91-100.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. NDIRANGU J , Newell ML, Thorne C, Bland R, et al
    Treating HIV-infected mothers reduces under 5 years of age mortality rates to levels seen in children of HIV-uninfected mothers in rural South Africa.
    Antivir Ther. 2012;17:81-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. LADA O , Gervais A, Branger M, Peytavin G, et al
    Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
    Antivir Ther. 2012;17:61-70.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. ZHANG C , McIlleron H, Ren Y, van der Walt JS, et al
    Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.
    Antivir Ther. 2012;17:25-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. JACKSON A , Moyle G, Dickinson L, Back D, et al
    Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
    Antivir Ther. 2012;17:19-24.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. SOBRINO-VEGAS P , Rodriguez-Urrego J, Berenguer J, Caro-Murillo AM, et al
    Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care.
    Antivir Ther. 2012;17:1-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2011
26. IMAZ A , Olmo M, Penaranda M, Gutierrez F, et al
    Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Antivir Ther. 2011 Dec 19. doi: 10.3851/IMP2025.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. DIAZ-DELFIN J , Domingo P, Wabitsch M, Giralt M, et al
    HIV-1 Tat protein impairs adipogenesis and induces the expression and secretion of proinflammatory cytokines in human SGBS adipocytes.
    Antivir Ther. 2011 Dec 16. doi: 10.3851/IMP2021.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. PATEL P , Bush T, Overton T, Baker J, et al
    Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
    Antivir Ther. 2011 Dec 16. doi: 10.3851/IMP2020.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. PAPASAVVAS E , Hsue P, Reynolds G, Pistilli M, et al
    Increased CD34(+)/KDR(+) cells are not associated with carotid artery intima-media thickness progression in chronic HIV-positive subjects.
    Antivir Ther. 2011 Dec 16. doi: 10.3851/IMP2013.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. POVEDA E , Vispo E, Barreiro P, de Mendoza C, et al
    Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
    Antivir Ther. 2011 Dec 15. doi: 10.3851/IMP1992.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. DONEGAN KL , Walker AS, Dunn D, Judd A, et al
    The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK.
    Antivir Ther. 2011 Dec 15. doi: 10.3851/IMP2015.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. BOGER MS , Bian A, Shintani A, Milne GL, et al
    Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy.
    Antivir Ther. 2011 Dec 14. doi: 10.3851/IMP1990.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. MCGEE KC , Shahmanesh M, Boothby M, Nightingale P, et al
    Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
    Antivir Ther. 2011 Dec 13. doi: 10.3851/IMP2017.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. DUARTE H , Matta JR, Muldoon N, Masur H, et al
    Non-calcified coronary plaque volume inversely related to CD4(+) T-cell count in HIV infection.
    Antivir Ther. 2011 Dec 7. doi: 10.3851/IMP1994.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. BARTH RE , Aitken SC, Tempelman H, Geelen SP, et al
    Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
    Antivir Ther. 2011 Dec 2. doi: 10.3851/IMP2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
36. CAPEL E , Auclair M, Caron-Debarle M, Capeau J, et al
    Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
    Antivir Ther. 2011 Nov 28. doi: 10.3851/IMP1988.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. DIAZ-BRITO V , Leon A, Knobel H, Peraire J, et al
    Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
    Antivir Ther. 2011 Nov 25. doi: 10.3851/IMP1955.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. WALLIS CL , Papathanasopolous MA, Fox M, Conradie F, et al
    Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
    Antivir Ther. 2011 Nov 18. doi: 10.3851/IMP1985.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. GALLI L , Spagnuolo V, Salpietro S, Gianotti N, et al
    Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy.
    Antivir Ther. 2011 Nov 18. doi: 10.3851/IMP1984.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. MUGUSI SF , Ngaimisi E, Janabi MY, Mugusi FM, et al
    Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.
    Antivir Ther. 2011 Nov 17. doi: 10.3851/IMP1956.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. LONGENECKER CT , Hileman CO, Carman TL, Ross AC, et al
    Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial.
    Antivir Ther. 2011 Nov 17. doi: 10.3851/IMP1983.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. KLINKLOM A , Puthanakit T, Gorowara M, Phasomsap C, et al
    Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Antivir Ther. 2011 Nov 10. doi: 10.3851/IMP1958.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. CRAUWELS H , Vingerhoets J, Ryan R, Witek J, et al
    Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.
    Antivir Ther. 2011 Nov 9. doi: 10.3851/IMP1959.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. ARENAS-PINTO A , Weller I, Ekong R, Grant A, et al
    Common inherited mitochondrial DNA mutations and nucleoside reverse transcriptase inhibitor-induced severe hyperlactataemia in HIV-infected adults: an exploratory study.
    Antivir Ther. 2011 Nov 7. doi: 10.3851/IMP1947.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. NACCARATO M , Yoong D, Kovacs C, Gough K, et al
    A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.
    Antivir Ther. 2011 Nov 4. doi: 10.3851/IMP1953.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. PALMER S , Boltz VF, Chow JY, Martinson NA, et al
    Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
    Antivir Ther. 2011 Nov 3. doi: 10.3851/IMP1946.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. SOGNI P , Carrieri MP, Fontaine H, Mallet V, et al
    The role of adherence in virological suppression in patients receiving anti-HBV analogues.
    Antivir Ther. 2011 Nov 3. doi: 10.3851/IMP1944.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
48. MURILLO O , Mimbrera D, Petit A, Gil H, et al
    Fatal bacillary angiomatosis mimicking an infiltrative vascular tumour in the immune restoration phase of an HIV-infected patient.
    Antivir Ther. 2011 Oct 21. doi: 10.3851/IMP1927.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. MCCOMSEY GA , O'Riordan M, Choi J, Libutti D, et al
    Mitochondrial function, inflammation, fat and bone in HIV lipoatrophy: randomized study of uridine supplementation or switch to tenofovir.
    Antivir Ther. 2011 Oct 13. doi: 10.3851/IMP1928.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
50. LLIBRE JM , Buzon MJ, Massanella M, Esteve A, et al
    Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Antivir Ther. 2011 Sep 28. doi: 10.3851/IMP1917.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. KOUANFACK C , Aghokeng AF, Mondain AM, Bourgeois A, et al
    Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
    Antivir Ther. 2011 Sep 23. doi: 10.3851/IMP1911.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
52. MASCOLINI M , Mellors JW, Richman DD, Boucher CA, et al
    HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies.
    Antivir Ther. 2011;16:263-86.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. BOYD SD , Maldarelli F, Sereti I, Ouedraogo GL, et al
    Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
    Antivir Ther. 2011;16:257-61.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. YOUNG B , Fransen S, Greenberg KS, Thomas A, et al
    Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.
    Antivir Ther. 2011;16:253-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. WELZEN ME , van den Berk GE, Hamers RL, Burger DM, et al
    Interaction between antiretroviral drugs and acenocoumarol.
    Antivir Ther. 2011;16:249-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. ARENAS-PINTO A , Grant A, Bhaskaran K, Copas A, et al
    Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis.
    Antivir Ther. 2011;16:219-226.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. THIBAULT V , Stitou H, Desire N, Valantin MA, et al
    Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients.
    Antivir Ther. 2011;16:199-205.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. POLSKY S , Floris-Moore M, Schoenbaum EE, Klein RS, et al
    Incident hyperglycaemia among older adults with or at-risk for HIV infection.
    Antivir Ther. 2011;16:181-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. SEVINSKY H , Eley T, Persson A, Garner D, et al
    The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
    Antivir Ther. 2011;16:149-56.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. HURT CB
    Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule.
    Antivir Ther. 2011;16:137-40.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. DE KANTER CT , Keuter M, van der Lee MJ, Koopmans PP, et al
    Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.
    Antivir Ther. 2011;16:435-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. CHARPENTIER C , Bellecave P, Cisse M, Mamadou S, et al
    High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
    Antivir Ther. 2011;16:429-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. RASSON S , Boyer S, Fugon L, Protopopescu C, et al
    Decentralization of access to antiretroviral therapy in Cameroon: correlates of HIV physicians' knowledge in HIV care.
    Antivir Ther. 2011;16:423-428.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. MCILLERON H , Ren Y, Nuttall J, Fairlie L, et al
    Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.
    Antivir Ther. 2011;16:417-21.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. TREVINO A , de Mendoza C, Parra P, Rodriguez C, et al
    Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
    Antivir Ther. 2011;16:413-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. STABINSKI L , Reynolds SJ, Ocama P, Laeyendecker O, et al
    High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda.
    Antivir Ther. 2011;16:405-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. SCHAPIRO JM , Boucher CA, Kuritzkes DR, van de Vijver DA, et al
    Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Antivir Ther. 2011;16:395-404.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. FAURE-PERRAUD A , Metifiot M, Reigadas S, Recordon-Pinson P, et al
    The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry, reverse transcription and integration.
    Antivir Ther. 2011;16:383-94.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. NASI M , Pinti M, Chiesa E, Fiore S, et al
    Decreased mitochondrial DNA content in subcutaneous fat from HIV-infected women taking antiretroviral therapy as measured at delivery.
    Antivir Ther. 2011;16:365-372.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
70. PILOTTO JH , Velasque LS, Friedman RK, Moreira RI, et al
    Maternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil.
    Antivir Ther. 2011;16:349-56.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. SORIANO V , Arasteh K, Migrone H, Lutz T, et al
    Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
    Antivir Ther. 2011;16:339-48.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
72. THIELEN A , Lengauer T, Swenson LC, Dong WW, et al
    Mutations in gp41 are correlated with coreceptor tropism but do not improve prediction methods substantially.
    Antivir Ther. 2011;16:319-28.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. ROCKSTROH JK , Peters L, Wedemeyer H
    Is there a need for liver disease monitoring in HIV patients in Africa?
    Antivir Ther. 2011;16:287-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. VAN DE VEN AA , Douma JW, Rademaker C, van Loon AM, et al
    Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.
    Antivir Ther. 2011;16:611-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. DLAMINI J , Ledwaba L, Mokwena N, Mokhathi T, et al
    Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.
    Antivir Ther. 2011;16:605-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. WYATT CM , Hoover DR, Shi Q, Tien PC, et al
    Pre-existing albuminuria predicts AIDS and non-AIDS mortality in women initiating antiretroviral therapy.
    Antivir Ther. 2011;16:591-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. TUMA P , Pineda JA, Labarga P, Vidal F, et al
    HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
    Antivir Ther. 2011;16:585-589.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
78. SCHERRENBURG J , Schellens IM, van Baarle D
    Influence of HIV infection on cytomegalovirus-specific immunity: T-cell responses to pp65 and IE1 before and after HAART may reflect altered cytomegalovirus biology.
    Antivir Ther. 2011;16:565-75.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
79. ROSS AC , Judd S, Kumari M, Hileman C, et al
    Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals.
    Antivir Ther. 2011;16:555-63.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. GIANELLA S , von Wyl V, Fischer M, Niederoest B, et al
    Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
    Antivir Ther. 2011;16:535-545.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
81. ORRELL C , Cohen K, Conradie F, Zeinecker J, et al
    Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Antivir Ther. 2011;16:527-34.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. BATMAN G , Oliver AW, Zehbe I, Richard C, et al
    Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells.
    Antivir Ther. 2011;16:515-25.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. BONORA S , Gonzalez de Requena D, D'Avolio A, Calcagno A, et al
    Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
    Antivir Ther. 2011;16:499-504.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
84. DE LUCA A , Di Giambenedetto S, Maserati R, Gianotti N, et al
    Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
    Antivir Ther. 2011;16:489-97.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
85. SAUMOY M , Ordonez-Llanos J, Martinez E, Barragan P, et al
    Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Antivir Ther. 2011;16:459-468.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
86. FOX ZV , Cozzi-Lepri A, D'Arminio Monforte A, Karlsson A, et al
    Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.
    Antivir Ther. 2011;16:781-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
87. GATHE J , Andrade-Villanueva J, Santiago S, Horban A, et al
    Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
    Antivir Ther. 2011;16:759-69.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
88. MCKINNON JE , Delgado R, Pulido F, Shao W, et al
    Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy.
    Antivir Ther. 2011;16:725-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
89. MOREN C , Noguera-Julian A, Rovira N, Garrabou G, et al
    Mitochondrial assessment in asymptomatic HIV-infected paediatric patients on HAART.
    Antivir Ther. 2011;16:719-24.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
90. 
    Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study.
    Antivir Ther. 2011;16:667-675.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
91. BIERMAN WF , van Vonderen MG, Veldkamp AI, Burger DM, et al
    The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
    Antivir Ther. 2011;16:647-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
92. VECCHIET J , Ucciferri C, Falasca K, Mancino P, et al
    Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients.
    Antivir Ther. 2011;16:639-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
93. SCOURFIELD A , Jackson A, Waters L, Gazzard B, et al
    The value of screening HIV-infected individuals for didanosine-related liver disease?
    Antivir Ther. 2011;16:941-2.
    PubMed     Text format     Related articles   
    
    
    
    
94. CHARPENTIER C , Larrouy L, Matheron S, Damond F, et al
    Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.
    Antivir Ther. 2011;16:937-940.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
95. CORNELISSEN M , Back NK, Burger DM, Blom P, et al
    Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy.
    Antivir Ther. 2011;16:931-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
96. KOZAL MJ , Chiarella J, St John EP, Moreno EA, et al
    Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
    Antivir Ther. 2011;16:925-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
97. BOENZLI E , Robert-Tissot C, Sabatino G, Cattori V, et al
    In vitro inhibition of feline leukaemia virus infection by synthetic peptides derived from the transmembrane domain.
    Antivir Ther. 2011;16:905-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
98. 
    Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe.
    Antivir Ther. 2011;16:895-903.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
99. VAN DEN EYNDE E , Quer J, Cubero M, Curran A, et al
    Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.
    Antivir Ther. 2011;16:887-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. JI H , Li Y, Graham M, Liang BB, et al
     Next-generation sequencing of dried blood spot specimens: a novel approach to HIV drug-resistance surveillance.
     Antivir Ther. 2011;16:871-8.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
101. LEVISON JH , Orrell C, Losina E, Lu Z, et al
     Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.
     Antivir Ther. 2011;16:853-61.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
102. LAUNAY O , Tod M, Tschope I, Si-Mohamed A, et al
     Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study.
     Antivir Ther. 2011;16:843-852.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. TURAL C , Sola R, Alvarez NP, Molto J, et al
     Effect of an induction period of pegylated interferon-alpha2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
     Antivir Ther. 2011;16:833-841.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
104. REIBERGER T , Obermeier M, Payer BA, Baumgarten A, et al
     Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting.
     Antivir Ther. 2011;16:815-24.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
105. NICASTRI E , Tommasi C, Abbate I, Bonora S, et al
     Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
     Antivir Ther. 2011;16:797-803.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
106. INNES S , Norman J, Smith P, Smuts M, et al
     Bioequivalence of dispersed stavudine: opened versus closed capsule dosing.
     Antivir Ther. 2011;16:1131-4.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
107. VAN MAARSEVEEN NM , Wensing AM, de Jong D, Beilhartz GL, et al
     Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans.
     Antivir Ther. 2011;16:1123-30.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
108. BUNUPURADAH T , Ananworanich J, Chetchotisakd P, Kantipong P, et al
     Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
     Antivir Ther. 2011;16:1113-21.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
109. D'ARMINIO MONFORTE A , Cozzi-Lepri A, Girardi E, Castagna A, et al
     Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome.
     Antivir Ther. 2011;16:1103-1112.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
110. BROWN TT , Ross AC, Storer N, Labbato D, et al
     Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
     Antivir Ther. 2011;16:1063-72.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
111. GRINSZTEJN B , Smeaton L, Barnett R, Klingman K, et al
     Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count.
     Antivir Ther. 2011;16:1057-1062.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
112. KORNER C , Tolksdorf F, Riesner K, Kramer B, et al
     Hepatitis C coinfection enhances sensitization of CD4(+) T-cells towards Fas-induced apoptosis in viraemic and HAART-controlled HIV-1-positive patients.
     Antivir Ther. 2011;16:1047-55.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
113. SVICHER V , Alteri C, Artese A, Zhang JM, et al
     Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.
     Antivir Ther. 2011;16:1035-1045.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
114. STOHR W , Reid A, Walker AS, Ssali F, et al
     Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
     Antivir Ther. 2011;16:1011-1020.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
115. ARENDS JE , van Assen S, Stek CJ, Wensing AM, et al
     Pegylated interferon-alpha monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
     Antivir Ther. 2011;16:979-88.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
116. MENENDEZ-ARIAS L
     A structural frame for understanding the role of thymidine analogue resistance mutations in resistance to zidovudine and other nucleoside analogues.
     Antivir Ther. 2011;16:943-6.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
117. KANJANAVANIT S , Puthanakit T, Vibol U, Kosalaraksa P, et al
     High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression.
     Antivir Ther. 2011;16:1351-1355.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
118. CHARPENTIER C , Gody JC, Tisserand P, Matta M, et al
     Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
     Antivir Ther. 2011;16:1347-50.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
119. KIM C , Gupta SK, Green L, Taylor BM, et al
     Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
     Antivir Ther. 2011;16:1335-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
120. PIEDOUX S , Monnet E, Piroth L, Montange D, et al
     Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
     Antivir Ther. 2011;16:1317-1326.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
121. CHOKEPHAIBULKIT K , Cressey TR, Capparelli E, Sirisanthana V, et al
     Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
     Antivir Ther. 2011;16:1287-1295.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
122. NIE T , Detorio M, Schinazi RF
     Universal profiling of HIV-1 pol for genotypic study and resistance analysis across subtypes.
     Antivir Ther. 2011;16:1267-75.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
123. VIGANO A , Mora S, Giacomet V, Stucchi S, et al
     In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
     Antivir Ther. 2011;16:1259-66.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
124. KENNEDY A , Hennessy M, Bergin C, Mulcahy F, et al
     Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients.
     Antivir Ther. 2011;16:1237-47.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
125. MARAIS D , Gawarecki D, Allan B, Ahmed K, et al
     The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection.
     Antivir Ther. 2011;16:1219-26.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
126. ELSE LJ , Taylor S, Back DJ, Khoo SH, et al
     Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
     Antivir Ther. 2011;16:1149-67.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
127. ELSE LJ , Taylor S, Back DJ, Khoo SH, et al
     Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
     Antivir Ther. 2011;16:1139-47.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
128. BARBER TJ , Geretti AM, Anderson J, Schwenk A, et al
     Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.
     Antivir Ther. 2011;16:805-14.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

This service is provided by AMEDEO through an unrestricted educational grant from Boehringer Ingelheim.

Amedeo is a Flying Publisher website.    Design: